The allosteric inhibitor asciminib shows clinical activity in heavily pretreated patients with chronic myeloid leukaemia who have failed or cannot tolerate tyrosine kinase inhibitors, including those who do not respond to ponatinib and harbour a T315I mutation, according to the results of a phase I dose-escalation study.
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.
Use of imatinib in the first-line treatment of children and adolescents with chronic myeloid leukaemia (CML) appears highly effective, yielding excellent response with tolerable side effects, according to the results of a single-arm phase III trial.
Use of bosutinib in the treatment of chronic myeloid leukaemia (CML) still proves to be more effective than imatinib, with a higher major molecular response rate, according to the 24-month follow-up data from the phase III BFORE* trial.
Vitamin C may halt the self-renewal of TET methylcytosine dioxygenase 2 (TET2)-deficient haematopoietic cells and suppress leukaemia progression, in addition to rendering the cells more susceptible to poly ADP ribose polymerase (PARP) inhibition, according to a study.
Nilotinib demonstrates potential in the first-line treatment of patients with chronic myeloid leukaemia, yielding sustained deep molecular response in a clinically significant percentage of patients, according to the results of the phase II ENESTfreedom trial. Importantly, nilotinib-treated patients may remain in treatment-free remission for up to 48 weeks after stopping nilotinib.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.